INS and steatosis: Randomized clinical studies in non-diabetic patients with thiazolidinediones, highly selective agonists for peroxisome proliferator-activated receptor gamma (PPARΥ) which sensitize adipose tissue to insulin actions and increase uptake of fatty acids in the liver, failed to show an improvement in liver enzyme levels, insulin resistance or a reduction in steatosis or inflammation.